Chemoradiotherapy +/- pembrolizumab in participants with MIBC

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

• IRAS ID

  1003217

• Contact name

  Ursula McGovern

• Contact email

  u.mcgovern@nhs.net

• Sponsor organisation

  Merck Sharp & Dohme (MSD)

• Eudract number

  2019-004023-20

• Clinicaltrials.gov Identifier

  NCT04241185

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  20/LO/0684

• Date of REC Opinion

  11 Jun 2020

• REC opinion

  Further Information Favourable Opinion